Opinion: Axis’ abortive reinsurance sale exacerbates its challenges
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Copy Link URLCopied!
  • Print
  • X
  • LinkedIn
  • Email
© 2024 Insider International Limited, company number 15236286, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian Group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

Opinion: Axis’ abortive reinsurance sale exacerbates its challenges

Rachel Dalton
11 May 2022
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Copy Link URLCopied!
  • Print
  • X
  • LinkedIn
  • Email
axis-new-with-benchimol-bermuda.jpg

Axis Capital’s sudden decision to pull the sale of its reinsurance unit – just a matter of weeks after putting it on the market – is a step that will make matters more difficult for the Bermudian.

This publication revealed in late April that Axis had appointed Jefferies to manage the sale of the ~$3bn unit.

The

Enter your e-mail to claim a free trial:

Uncover exclusive insights tailored for insurance leaders

    • Stay Informed: Access exclusive industry insights
    • Gain a competitive advantage: Hear first about tactical developments
    • Make better decisions: Understand market dynamics in crucial lines of business
Take a free trial Already a subscriber? Login now

Topics

OpinionM&AAxis Capital
rachel dalton 2024 ii red 2.png
Rachel Dalton
Lead Reporter
Contact
Gift this article